Androgen receptor: role and novel therapeutic prospects in prostate cancer

References

• Caskey C, Pizzuti A, Fu Y-H, Fenwick R, Nelson D. Triplet repeat mutations in human disease. Science256, 784–789 (1992).
   PubMed Web of Science ®Google Scholar
• Griffin J. Androgen resistance – the clinical and molecular spectrum NEJM326, 611–618 (1992).
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges C. The effect of castration, of oestrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.1, 293–297 (1941).
   Google Scholar
• Mohler J, Gregory C, Ford OH et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res.10, 440–448 (2004).
   PubMed Web of Science ®Google Scholar
• Montgomery R, Mostaghel E, Vessella R et al. Maintance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68, 4447–4459 (2008).
   PubMed Web of Science ®Google Scholar
• Mostaghel E, Page S, Lin D et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res.67, 5033–5041 (2007).
   PubMed Web of Science ®Google Scholar
• Ryan C, Halabi S, Ou S, Vogelzang N, Kantoff P, Small E. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin. Cancer Res.13(7), 2030–2037 (2007).
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley G, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res.66, 2815–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Titus M, Schell M, Lin F, Tomer K, Mohler J. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res.11(13), 4653–4657 (2005).
   PubMed Web of Science ®Google Scholar
• Evans R. The steroid and thyroid hormone receptor super family. Science240, 889–895 (1988).
   PubMed Web of Science ®Google Scholar
• Pratt W, Toft D. Steroid receptor interactions with heat shock protein and immunophilin charperones. Endocr. Rev.18, 306–360 (1997).
   PubMed Web of Science ®Google Scholar
• Veldscholte J, Berrevoets C, Zegers N, van der Kwast TH, Grootegoed J, Mulder E. Hormone-induced dissociation of the androgen receptor-heat shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry31, 7422–7430 (1992).
   Google Scholar
• Wilson J. Role of dihydrotestosterone in androgen action. Prostate Suppl.6, 88–92 (1996).
   Google Scholar
• Dehm SM, Tindall DJ. Regulation of androgen receptor signaling in prostate cancer. Expert Rev. Anticancer Ther.5, 63–74 (2005).
   PubMed Web of Science ®Google Scholar
• Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol. Cell9, 601–610 (2002).
   PubMed Web of Science ®Google Scholar
• Chang C-Y, McDonnell D. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharm. Sci.26, 225–228 (2005).
   PubMed Web of Science ®Google Scholar
• Mckenna J, Lanz R, O’Malley B. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev.20(3), 321–344 (1999).
   PubMed Web of Science ®Google Scholar
• Dehm S, Tindall D. Molecular regulation of androgen action in prostate cancer. J. Cell. Biochem.99, 333–344 (2006).
   PubMed Web of Science ®Google Scholar
• Heinein C, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol.16, 2181–2187 (2002).
   Google Scholar
• Balk S, Knudsen K. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal.6, e001 (2008).
   PubMedGoogle Scholar
• Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH. Androgen receptor expression in human tissues: an immunohistochemical study. J. Histochem. Cytochem.39, 927–936 (1991).
   PubMed Web of Science ®Google Scholar
• Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayali G. High level of andorgen receptor is associated with aggressive cliniopathologic features and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Am. J. Surg. Path.28, 928–934 (2004).
   PubMed Web of Science ®Google Scholar
• Mari R, Wang Q, Tarabolous C et al. Prognostic value of the androgen receptor and its coactivators in prostate cancer patients with D1 prostate cancer. Anticancer Res.28, 425–430 (2008).
   Google Scholar
• Ricciardelli C, Choong C, Vivekanadan S et al. AR levels in prostate cancer epithelium and peritumoral stromal cells identify non-organ confined disease. Prostate63, 19–28 (2005).
   PubMed Web of Science ®Google Scholar
• Palazzolo I, Gliozzi A, Rusmini P et al. The role of the polyglutamine tract in androgen receptor. J. Steroid Biochem. Mol. Biol.108(3–5), 245–253 (2008).
   PubMed Web of Science ®Google Scholar
• Sasaki M, Tanaka Y, Perinchery G et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J. Natl Cancer Inst.94(5), 384–390 (2002).
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Stampfer M, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA94, 3320–3323 (1997).
   PubMed Web of Science ®Google Scholar
• Irvine R, Yu M, Ross R, Coetzee G. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res.55, 1937–1940 (1995).
   PubMed Web of Science ®Google Scholar
• Sircar K, Gottlieb B, Alvarado C et al. Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer Prostatic Dis.10(4), 360–368 (2007).
   Google Scholar
• Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem.91, 483–490 (2004).
   PubMed Web of Science ®Google Scholar
• Balic I, Graham ST, Troyer DA et al. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J. Urol.168(5), 2245–2248 (2002).
   PubMed Web of Science ®Google Scholar
• Chamberlain N, Driver E, Miesfeld R. The length and location of the CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res.22, 3181–3186 (1994).
   PubMed Web of Science ®Google Scholar
• Choong C, Kemppainen J, Zhou Z, Wilson E. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol. Endocrinol.10, 1527–1535 (1996).
   PubMedGoogle Scholar
• Lange E, Sarmer A, Ray A et al. The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African American men: results from the Flints Men’s Health Study. J. Hum. Genet.53, 220–226 (2008).
   Google Scholar
• Zeeger M, Kiemeney L, Nieder A, Ostrer H. How strong is the association between CAG and GGN repeat length polymorphism in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol. Biomarkers Prev.13, 1765–1771 (2004).
   Google Scholar
• Eisenberger M, Blumenstein B, Crawford E, Miller G, McLeod D. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. NEJM339, 1036–1042 (1998).
   PubMed Web of Science ®Google Scholar
• Moul J, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J. Urol.171, 1141–1147 (2004).
   PubMed Web of Science ®Google Scholar
• Ross R, Oh W, Xie W et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J. Clin. Oncol.26(6), 842–847 (2008).
   PubMedGoogle Scholar
• Bubendorf L, Kononen J, Koivisto P et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res.59, 803–806 (1999).
   PubMed Web of Science ®Google Scholar
• Edwards J, Krishna N, Grigor K, Bartlett J. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer89, 552–556 (2003).
   PubMed Web of Science ®Google Scholar
• Ford OH, Gregory C, Kim D, Smitherman AB, Mohler J. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol.170, 1817–1821 (2003).
   PubMed Web of Science ®Google Scholar
• Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res.57, 314–319 (1997).
   PubMed Web of Science ®Google Scholar
• Linja M, Savinainen K, Saramaki O, Tammela T, Vessella R, Visakorpi T. Amplification and over expression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res.61, 3550–3555 (2001).
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P et al.In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet.9, 401–406 (1995).
   PubMed Web of Science ®Google Scholar
• Palmberg C, Koivisto P, Tammela TI, Kallioniemi O-P, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol.164, 1992–1995 (2000).
   PubMed Web of Science ®Google Scholar
• Veldscholte J, Kuiper G, Jenster G et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun.173, 534–540 (1990).
   PubMed Web of Science ®Google Scholar
• Gottlieb B, Beitel L, Wu J, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat.23, 527–533 (2004).
   PubMed Web of Science ®Google Scholar
• Gelmann E. Molecular biology of the androgen receptor. J. Clin. Oncol.20, 3001–3015 (2002).
   PubMed Web of Science ®Google Scholar
• Taplin M, Bubley G, Ko Y et al. Selection for androgen receptor mutations in prostate cancer treated with androgen antagonist. Cancer Res.59, 2511–2515 (1999).
   PubMed Web of Science ®Google Scholar
• Fenton M, Shuster T, Furtig A et al. Functional characterization of mutant androgen receptors from androgen independent prostate cancer. Clin. Cancer Res.3, 1383–1388 (1997).
   PubMed Web of Science ®Google Scholar
• Joyce R, Fenton M, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol.159, 149–153 (1998).
   PubMed Web of Science ®Google Scholar
• Taplin ME, Rajeshkumar B, Halabi S et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol.21, 2673–2678 (2003).
   PubMed Web of Science ®Google Scholar
• Miyamto H, Rahman M, Chang C. Molecular basis for antiandrogen withdrawal syndrome. J. Cell. Biochem.91, 3–12 (2004).
   Google Scholar
• Culig Z, Hobisch A, Cronauer M et al. Mutant androgen receptor detected in an advanced-stage prostate carcinoma is activated by adrenal androgen and progesterone. Mol. Endocrinol.7, 1541–1550 (1993).
   PubMed Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer M et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect. Prev.20, 68–75 (1996).
   PubMedGoogle Scholar
• Zhao X, Malloy P, Krishnan A et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med.6, 703–706 (2000).
   PubMed Web of Science ®Google Scholar
• Buchanan G, Yang M, Harris J et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol.15, 46–56 (2001).
   PubMed Web of Science ®Google Scholar
• Ceraline J, Cruchant M, Erdmann E et al. constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int. J. Cancer108, 152–157 (2004).
   PubMed Web of Science ®Google Scholar
• Gregory C, He B, Johnson R et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res.61, 4315–4319 (2001).
   PubMed Web of Science ®Google Scholar
• Halkidou K, Gnanapragasam V, Mehta P et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene22, 2466–2477 (2003).
   PubMed Web of Science ®Google Scholar
• Papaioannou M, Reeb C, Asim M, Dotzlaw H, Baniahmad A. Co-activator and co-repressor interplay on the human androgen receptor. Andrologia37, 211–213 (2005).
   Google Scholar
• Ueda T, Bruchovsky N, Sadar M. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem.277, 7076–7085 (2002).
   PubMed Web of Science ®Google Scholar
• Grossmann M, Huang H, Tindall D. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl Cancer Inst.93, 1687–1697 (2001).
   PubMed Web of Science ®Google Scholar
• Ford C, Skiba N, Bae H et al. Molecular basis for interactions of G proteins bg subunits with effectors. Science280, 1271–1274 (1998).
   PubMed Web of Science ®Google Scholar
• Kasbohm E, Guo R, Yowell C et al. Androgen receptor activation by Gs signaling in prostate cancer cells. J. Biol. Chem.280, 11583–11589 (2005).
   Google Scholar
• Waxman J, Wass J, Hendry W et al. Treatment with gonadotropin-releasing hormone analogue in advanced prostatic cancer. BMJ286, 1309–1312 (1983).
   PubMed Web of Science ®Google Scholar
• Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int.91, 455–461 (2003).
   PubMed Web of Science ®Google Scholar
• Small E, Ryan C. The case for secondary hormonal therapies in the chemotherapy age. J. Urol.176, S66–S71 (2006).
   Google Scholar
• Gao W, Dalton J. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm. Res.23, 1641–1658 (2006).
   PubMed Web of Science ®Google Scholar
• Nakabayaski M, Regan M, Lifsey D et al. Efficacy of nilutamide as secondary hormone therapy in androgen independent prostate cancer. BJU Int.96, 783–786 (2005).
   Google Scholar
• Scher H, Liebetz C, Kelly W et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol.15, 2928–2938 (1997).
   PubMed Web of Science ®Google Scholar
• Bohl C, Gao W, Miller D, Bell C, Dalton J. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl Acad. Sci. USA102, 6201–6206 (2005).
   PubMed Web of Science ®Google Scholar
• Small E, Halabi S, Dawson N et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a Phase III trial (CALGB 9583). J. Clin. Oncol.22, 1025–1033 (2004).
   PubMed Web of Science ®Google Scholar
• Pomerantz M, Manola J, Taplin M et al. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J. Urol.177, 2146–2150 (2007).
   PubMed Web of Science ®Google Scholar
• D’Amico A, Kantoff P, Chen M. Aspirin and hormone therapy for prostate cancer. NEJM357(26), 2737–2738 (2007).
   Google Scholar
• Bhanalaph T, Varkarakis M, Murphy G. Current status of bilateral adrenalectomy on advanced prostate carcinoma. Ann. Surg.179, 17–23 (1974).
   Google Scholar
• Attard G, Belldegrun AS, deBono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int.96, 1241–1246 (2005).
   PubMed Web of Science ®Google Scholar
• Miller W, Auchus R, Geller D. The regulation of 17, 20 lyase activity. Steroids62, 133–142 (1997).
   PubMed Web of Science ®Google Scholar
• Danila D, Rathkopf D, Fleisher M et al. Preliminary Phase II results of abiraterone acetate in patients with castration-resistant metastatic prostate cancer after failure of docetaxel-based chemotherapy. Genitourinary Cancers Symposium Proceedings Book. American Society of Clinical Oncology, VA, USA 97 (2008) (Abstract 3).
   Google Scholar
• Reid A, Attard G, Molife R et al. Selective CYP17 inhibition with abiraterone acetate (AA) results in a high response rate (RR) in castration-resistant prostate cancer (CRPC) confirming the continued importance of targeting androgen receptor (AR) signaling. Genitourinary Cancers Symposium Proceedings Book. American Society of Clinical Oncology, VA, USA 120 (2008) (Abstract 50).
   Google Scholar
• Thompson I, Goodman P, Tangen D et al. The influence of finasteride on the development of prostate cancer. NEJM349, 215–224 (2003).
   PubMed Web of Science ®Google Scholar
• Andriole G, Humphrey P, Ray P et al. Effect of the dual 5-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J. Urol.172, 915–919 (2004).
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Laufer M, Vogelzang N et al. Phase I and clinical pharmacology of a type I and II, 5-a-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology63, 114–119 (2004).
   Google Scholar
• Brown T. Nonsteroidal selective androgen receptor modulators (SARMs): designer androgen with flexible structures provide clinical promise. Endocrinology145(12), 5420–5428 (2004).
   Google Scholar
• Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet355, 1491–1498 (2000).
   PubMed Web of Science ®Google Scholar
• Samson D, Seidenfeld J, Schmitt B et al. Systemic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer95, 361–376 (2002).
   PubMed Web of Science ®Google Scholar
• Baek S, Ohgi K, Nelson C et al. Ligand specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc. Natl Acad. Sci.USA1033100–3105 (2006).
   PubMed Web of Science ®Google Scholar
• Furr B. Casodex: preclinical studies and controversies. Ann. NY Acad. Sci.761, 79–96 (1995).
   Google Scholar
• Salvati M, Balog A, Wei D et al. Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. Bioorg. Med. Chem. Lett.15, 389–393 (2005).
   PubMed Web of Science ®Google Scholar
• Ellwood Y, Wonguipat J, Sawyers C. Transgenic mouse model for rapid pharmocodynamic evaluation of antiandrogens. Cancer Res.66, 10513–10516 (2006).
   Google Scholar
• Scher HI, Beer TM, Higano CS et al. Phase I/II study of MDV3100 in patients with progressive castration resistant prostate cancer. J. Clin. Oncol.26(Suppl. 15S), 26 (2008) (Abstract 5006).
   Google Scholar
• Handratta V, Vasaitis T, Njar V et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics and antitumor activity in the LAPC4 human prostate xenograft model. J. Med. Chem.48, 2972–2984 (2005).
   PubMed Web of Science ®Google Scholar
• Schayowitxz A, Sabnis G, Njar V, Brodie A. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol. Cancer Ther.7, 121–132 (2008).
   Google Scholar
• Hodgson M, Astapova I, Cheng S et al. The androgen receptor recruits nuclear receptor corepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem.280, 6511–6519 (2005).
   PubMed Web of Science ®Google Scholar
• Taplin M, Manola J, Oh W et al. A Phase II trial of mifepristone (RU-486) in castration-resistant prostate cancer with correlative assessment of androgen-related hormones. BJU Int.101, 1084–1089 (2008).
   Google Scholar
• Powers M, Workman P. Targeting of multiple signaling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. Relat. Cancer13, S125–S136 (2006).
   PubMed Web of Science ®Google Scholar
• Prodromou C, Pearl L. Structure and functional relationships of Hsp 90. Curr. Cancer Drug Targets3, 301–323 (2003).
   PubMed Web of Science ®Google Scholar
• Banerji U, O’Donnell A, Scurr M et al. Phase I pharmacokinetic and pharmacodynamic study of 17-Allylamino, 17-demethoxygeldannmycin in patients with advanced malignancies. J. Clin. Oncol.23, 4152–4161 (2005).
   PubMed Web of Science ®Google Scholar
• Solit D, Scher H, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin. Oncol.30, 709–716 (2003).
   PubMed Web of Science ®Google Scholar
• Goetz M, Toft D, Reid J et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol.23, 1978–1087 (2005).
   Google Scholar
• Grem J, Morrison G, Guo X et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol.23, 1885–1893 (2005).
   PubMed Web of Science ®Google Scholar
• Hollingshead M, Alley M, Burger A et al.In vivo antitumor efficacy of 17-DMAG (17-diethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water soluable geldanancycin derivative. Cancer Chemother. Pharmacol.56, 115–125 (2005).
   PubMed Web of Science ®Google Scholar
• Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnoiss and treatment of prostate cancer and benign prostateic hyperplasia. J. Urol.177, 822–831 (2007).
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci G. Histone deacetylase inhibitiors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer6, 38–51 (2006).
   PubMed Web of Science ®Google Scholar
• Qian D, Kato Y, Shabbeer S et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res.12, 634–642 (2006).
   PubMed Web of Science ®Google Scholar
• Dashwood R, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin. Cancer Biol.17, 363–369 (2007).
   PubMed Web of Science ®Google Scholar
• Wedel S, Sparatore A, Soldato P et al. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate cancer. J. Cell Mol. Med. (2008). (Epub ahead of print).
   Google Scholar
• Carducci M, Gilbert J, Bowling M et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res.7, 3047–3055 (2001).
   PubMed Web of Science ®Google Scholar
• Kelly W, Richon V, O’Connor O et al. Phase I clinical trial of histone deactylase inhibitor: suberylanilide hydroxamic acid (SAHA). Clin. Cancer Res.9, 3578–3588 (2003).
   PubMed Web of Science ®Google Scholar
• Schayowitz A, Sabnis G, Njar V, Brodie A. Synergistic effect of a novel antiandrogen VN/124–1 and signal transduction inhibition in prostate cancer progression to hormone independence in vitro. Mol. Cancer Ther.7, 121–132 (2008).
   PubMed Web of Science ®Google Scholar
• Morris M, Reuter V, Kelly W et al. HER-2 profiling and targeting in prostate carcinoma. Cancer94, 980–986 (2002).
   PubMed Web of Science ®Google Scholar
• Nicholson B, Gulding K, Conaway M et al. Combined antiangiogenesis and androgen deprivation therapy for prostate cancer: a promising therapeutic application. Clin. Cancer Res.10, 8728–8734 (2004).
   Google Scholar
• Cai Y, Lee Y, Li G et al. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibition. Int. J. Cancer123(1), 195–201 (2008).
   Google Scholar
• Solit D, Egorin M, Valentin G et al. Phase I pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeladanamycin). J. Clin. Oncol.22(203), (2004) (Abstract 3032).
   Google Scholar
• Sankaranarayanapillai M, Tong W, Maxwell D et al. Detection of histone deacetylase inhibition by nonivasive magnetic resonance spectroscopy. Mol. Cancer Ther.5, 1325–1334 (2006).
   Google Scholar
• Marquis J, Hillier S, Dinaut A et al. Disruption of gene expression and induction of apoptosis in prostate cancer cells by a DNA-damaging agent tethered to an androgen receptor ligand. Chem. Biol.12, 779–787 (2005).
   PubMed Web of Science ®Google Scholar
• Haag P, Bektic J, Bartsch G, Klocker H, Eder I. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J. Steroid Biochem. Mol. Biol.96, 251–258 (2005).
   PubMed Web of Science ®Google Scholar
• Gao W, Bohl C, Dalton J. Chemical and structural biology of androgen receptor. Chem. Rev.105, 3352–3370 (2005).
   PubMed Web of Science ®Google Scholar
• Page ST, Lin DW, Mostaghel EA et al. Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J. Clin. Endocrinol. Metab.91, 3850–3856 (2006)
   PubMed Web of Science ®Google Scholar